Zobrazeno 1 - 10
of 65
pro vyhledávání: '"Dallas, Mari H."'
Autor:
Epperly, Rebecca, Li, Ying, Selukar, Subodh, Zeng, Emily, Madden, Renee, Mamcarz, Ewelina, Naik, Swati, Qudeimat, Amr, Sharma, Akshay, Talleur, Aimee, Dallas, Mari H., Gottschalk, Stephen, Srinivasan, Ashok, Triplett, Brandon
Publikováno v:
In Transplantation and Cellular Therapy May 2024 30(5):526-526
Publikováno v:
In Biology of Blood and Marrow Transplantation January 2015 21(1):39-49
Autor:
Pereda, Maria A., Hosahalli Vasanna, Smitha, Desai, Neha J., Deng, Victoria, Owusu-Ansah, Amma, Dallas, Mari H., Pateva, Irina, Dalal, Jignesh
Publikováno v:
Frontiers in Immunology. 13
Daratumumab, a CD38 monoclonal antibody that has been FDA-approved to treat multiple myeloma, has acquired popularity and is used off-label for both auto- and alloantibody mediated disorders, particularly in refractory/resistant circumstances. Much o
Autor:
Srinivasan, Ashok, Panetta, John C., Cross, Shane J., Pillai, Asha, Triplett, Brandon M., Shook, David R., Dallas, Mari H., Hartford, Christine, Sunkara, Anusha, Kang, Guolian, Jacobsen, Jeffrey, Choi, John, Leung, Wing
Publikováno v:
In Biology of Blood and Marrow Transplantation August 2014 20(8):1224-1228
Autor:
Dallas, Mari H., Triplett, Brandon, Shook, David R., Hartford, Christine, Srinivasan, Ashok, Laver, Joseph, Ware, Russell, Leung, Wing
Publikováno v:
In Biology of Blood and Marrow Transplantation May 2013 19(5):820-830
Autor:
Shook, David R., Triplett, Brandon M., Srinivasan, Ashok, Hartford, Christine, Dallas, Mari H., Pillai, Asha, Laver, Joseph, Leung, Wing
Publikováno v:
In Biology of Blood and Marrow Transplantation February 2013 19(2):291-297
Publikováno v:
In Blood 1 March 2008 111(5):2615-2620
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
In Biology of Blood and Marrow Transplantation January 2015 21(1):130-136
After hematopoietic stem cell transplantation (HSCT), successful engraftment and immune recovery is necessary to protect the patient from relapse and infection. Many studies highlight the importance of conventional αβ T cell recovery after HSCT, bu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::dbee21ea128f64d774e67b00029accdf
https://europepmc.org/articles/PMC4288038/
https://europepmc.org/articles/PMC4288038/